Odyssey Therapeutics, Inc. (ODTX) Income Statement
ODTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsODTX revenue and net income
Where ODTX's revenue goes
2025Each bar shows an amount and its share of revenue. ODTX kept −4,994.9% of revenue as net income.
ODTX profit margins
ODTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −33.5% | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ODTX quarterly EPS vs estimates
Odyssey Therapeutics beat the analyst EPS estimate in 0 of the last 2 quarters. Next report: November 4, 2026 (estimate $-1.13).
ODTX income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $3.0M | $4.5M | $1.0M | $0 |
| Cost of revenue | $0 | — | — | — |
| Gross profit | $3.0M | — | — | — |
| Research & development | $126.6M | $112.6M | $112.3M | $101.8M |
| Sales, general & admin | $37.5M | $27.1M | $22.2M | $21.0M |
| Total operating expenses | $164.1M | $139.7M | $134.5M | $122.8M |
| Operating income | −$161.2M | −$135.2M | −$133.4M | −$122.8M |
| Interest income | $6.3M | $8.5M | $8.8M | $3.9M |
| Interest expense | $17,000 | $18,000 | $335,000 | $291,000 |
| Income before taxes | −$149.6M | −$128.9M | −$125.5M | −$124.3M |
| Income taxes | −$927,000 | — | — | — |
| Net income | −$148.6M | −$129.3M | −$125.9M | −$124.7M |
| EBITDA | −$144.6M | −$123.6M | −$120.2M | −$121.3M |
| EPS (diluted) | — | −$2.74 | — | — |
| Gross margin | 100.0% | — | — | — |
| Operating margin | −5,415.2% | −3,023.8% | −12,867.8% | — |
| Net margin | −4,994.9% | −2,891.8% | −12,144.5% | — |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $959,000 | $1.9M | $1.8M |
| Research & development | $36.2M | $32.3M | $30.2M | $38.8M | $31.5M |
| Sales, general & admin | $10.5M | $7.3M | $13.2M | $8.0M | $7.4M |
| Total operating expenses | $55.5M | $39.8M | $43.4M | $46.7M | $38.9M |
| Operating income | −$55.5M | −$39.8M | −$42.5M | −$44.8M | −$37.1M |
| Interest income | $2.8M | $1.7M | $872,000 | $1.2M | $1.8M |
| Interest expense | $20,000 | $10,000 | $2,000 | $2,000 | $4,000 |
| Income before taxes | −$52.8M | −$38.2M | −$41.2M | −$38.3M | −$35.9M |
| Income taxes | −$8,000 | $63,000 | — | — | — |
| Net income | −$52.8M | −$38.3M | −$41.2M | −$38.4M | −$35.9M |
| EBITDA | −$51.7M | −$37.0M | −$39.9M | −$37.0M | −$34.6M |
| EPS (diluted) | −$1.26 | −$6.75 | — | — | — |
| Operating margin | — | — | −4,430.3% | −2,336.2% | −2,115.2% |
| Net margin | — | — | −4,299.8% | −2,003.9% | −2,047.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ODTX's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ODTX financial results
In fiscal year 2025 (ended December 31, 2025), Odyssey Therapeutics reported revenue of $3.0 million, down 33.5% from the year before. It had a net loss of $148.6 million, a net profit margin of −4,994.9%.
See the ODTX stock overview for the latest quote and news, or the ODTX chart for price history and technical indicators.
ODTX income statement FAQ
What is Odyssey Therapeutics's annual revenue?
Odyssey Therapeutics reported total revenue of $3.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 33.5% from $4.5 million the previous year.
Is Odyssey Therapeutics profitable?
No. Odyssey Therapeutics reported a net loss of $148.6 million in fiscal 2025, a net profit margin of −4,994.9%; its operating margin was −5,415.2%.
What is Odyssey Therapeutics's gross margin?
Odyssey Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Odyssey Therapeutics kept $100 after the direct cost of its products and services.
How much does Odyssey Therapeutics spend on research and development?
Odyssey Therapeutics spent $126.6 million on research and development in fiscal 2025, 4,254.6% of revenue.
When will Odyssey Therapeutics report its next earnings?
Odyssey Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Odyssey Therapeutics's fiscal year end?
Odyssey Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.